Botulinum toxin type B (Myobloc™, NeuroBloc™): a new choice in cervical dystonia

References

• Nutt JG, Muenter MD, Melton LJ III, Aronson A, Kurland LT Epidemiology of dystonia in Rochester, Minnesota. Adv. Neural. 50, 361–365 (1988).
   PubMedGoogle Scholar
• Rondot P, Marchand MP, Dellatolas G. Spasmodic torticollis — review of 220 patients. Can. Neural Sc]. 18, 143–151 (1991).
   Google Scholar
• Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. May. Disord 6, 119–126 (1991).
   Google Scholar
• Kutvonen O, Dastidar P, Nurmikko T Pain in spasmodic torticollis. Pain 69, 279–286 (1997).
   PubMed Web of Science ®Google Scholar
• Lobbezoo F, Tanguay R, Thu Thon M, Lavigne GJ. Pain perception in idiopathic cervical dystonia (spasmodic torticollis). Pain 67, 483–491 (1996).
   PubMed Web of Science ®Google Scholar
• Jahanshahi M, Marsden CD. Psychological functioning before and after treatment of torticollis with botulinum toxin. j Neural. Neurosurg. Psychiatry55, 229–231 (1992).
   PubMed Web of Science ®Google Scholar
• Jahanshahi M. Psychosocial factors and depression in torticollis. j fiychosom. Res. 35, 493–507 (1991).
   PubMed Web of Science ®Google Scholar
• Fahn S. Systemic therapy for dystonia. Can. J. Neural. Sc]. 14, 528–532 (1987).
   PubMed Web of Science ®Google Scholar
• Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. May Disord 3, 46–60 (1988).
   Google Scholar
• Dauer WT, Burke RE, Greene P, Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 121, 547–560 (1998).
   PubMed Web of Science ®Google Scholar
• •This paper provides a good review of the etiology and management of cervical dystonia.
   Google Scholar
• Bertrand CM. Selective peripheral denervation for spasmodic torticollis: surgical technique, results and observations in 260 cases. Surg. Neural 40, 96–103 (1993).
   Google Scholar
• Ford B, Louis ED, Greene P, Fahn S. Outcome of selective ramisectomy for botulinum toxin resistant torticollis. Neural. Neurosurg. fiychiatry65, 472–478 (1998).
   PubMed Web of Science ®Google Scholar
• Krauss JK, Toops EG, Jankovic J, Grossman RG. Symptomatic and functional outcome of surgical treatment of cervical dystonia. j Neural. Neurosurg. Psychiatry 63, 642–648 (1997).
   PubMed Web of Science ®Google Scholar
• LeWitt AP, Trosch RM. Idiosyncratic adverse reactions to im. botulinum toxin type A injection. May Disord. 12(6), 1064–1067 (1997).
   PubMed Web of Science ®Google Scholar
• Tsui JKC, Fross RD, Caine S, Caine DB. Local treatment of spasmodic torticollis with botulinum toxin. Can. j Neural. Sc]. 14(3 Suppl.), 533–535 (1987).
   Google Scholar
• Jankovic J, Brin M. Therapeutic uses of botulinum toxin. N Engl. J. Med. 324, 1186–1194 (1991).
   PubMed Web of Science ®Google Scholar
• Jankovic J. Medical therapy and botulinum toxin in dystonia. In: Dystonia 3: Advances in Neurology Fahn S, Marsden CD, DeLong M, (Eds.), Lippincott-Raven publishers, Philadephia, USA 169–183 (1998).
   Google Scholar
• Mahant N, Clouston PD, Lorentz IT The current use of botulinum toxin. j Clin. Neuroscience 7, 389–394 (2000).
   Google Scholar
• •A nice simplified review of the many clinical uses of botulinum toxin.
   Google Scholar
• Arnon SS, Schechter R, Inglesby TV et al. Botulinum toxin as a biological weapon. JAIVIA 285(8), 1059–1070 (2001).
   PubMed Web of Science ®Google Scholar
• Eleopra R, Tugnoli V, Rossetto O, Montecucco C, De Grandis D. Botulinum neurotoxin serotype C: a novel effect botulinum toxin in human. Neumsci. Lett. 24, 91–94 (1997).
   Google Scholar
• Greene PE, Fahn S. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A. May. Disord. 8, 479–483 (1993).
   PubMed Web of Science ®Google Scholar
• Houser MK, Sheean GL, Lees AJ. Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A. j Neural. Neurosurg. Psychiatry 64, 577–580 (1998).
   Google Scholar
• Mezaki T, Kaji R, Kohara N et al Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology45, 506–508 (1995).
   PubMed Web of Science ®Google Scholar
• Borodic G, Johnson E, Goodnough M, Schantz E. Botulinum toxin therapy, immunologic resistance and problems with available materials. Neurology 46, 26–29 (1996).
   PubMed Web of Science ®Google Scholar
• Sankhla C, Jankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov. Disoml 13(1), 150–154 (1998).
   Google Scholar
• Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A patients with torticollis. May Disoni 9, 213–217 (1994).
   Google Scholar
• Jankovic J, Schwartz KS. Response and immunoresistance to botulinum toxin injections. Neurology 45, 1743–1746 (1995).
   PubMed Web of Science ®Google Scholar
• Setler P. The biochemistry of botulinum toxin type B. Neurology55\(Suppl. 5), S23—S28 (2000).
   Google Scholar
• Jankovic J, Schwartz KS. Clinical correlates of response to botulinum toxin injections. Arch. Neural. 48, 1253–1256 (1991).
   PubMedGoogle Scholar
• Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology43, 1715–1718 (1992).
   Web of Science ®Google Scholar
• Aoki KR. Preclinical update on Botox® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur. Neural. 6 (Suppl. 4), S3—S10 (1999).
   Google Scholar
• Lange DI, Rubin M, Greene PE et al Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 14, 672–675 (1991).
   PubMed Web of Science ®Google Scholar
• Olney RK, Aminoff MJ, Gelb DJ et al Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology38, 1780–1783 (1988).
   PubMed Web of Science ®Google Scholar
• Bhatia KP, Manchau A, Thompson PD et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J. Neural. Neurosurg. Psychiatry 67, 90–93 (1999).
   PubMed Web of Science ®Google Scholar
• Sakaguchi G. Clostridium botulinurntoxins. Pharmacol Ther 19, 165–194 (1983).
   Web of Science ®Google Scholar
• •A good review of the pharmacologic similarities and differences among toxin serotypes.
   Google Scholar
• Sugiyama H. Clostridium bort/lima] neurotoxin. Microbial. Rev 44, 419–448 (1980).
   PubMedGoogle Scholar
• Johnson EA, Goodnough MC. Preparation and properties of botulinum toxin for medical use. In: Handbook of dystonia. Tsui JKC, Caine DB, (Eds.), Marcel Dekker, New York, USA 346–365 (1995).
   Google Scholar
• Schantz EJ, Johnson EA. Quality of botulinum toxin for human treatment. In: Botulinum and tetanus neurotoxins. DasGupta BR, (Ed.), Plenum Press, New York, USA 657–659 (1993).
   Google Scholar
• Montecucco C, Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q. Rev Biophys. 28, 423–472 (1995).
   PubMed Web of Science ®Google Scholar
• Sugiyama H, Das Gupta R, Yang KH. Disulfide-toxicity relationship of botulinal toxin types A, E and E Proc Soc. Exp. Biol. Med. 143, 589–591 (1973).
   Web of Science ®Google Scholar
• Bavari S, Pless DD, Torres ER et al. Identifying the principal protective antigenic determinants of type A botulinum neurotoxin. Vaccine 16, 1850–1856 (1998).
   PubMed Web of Science ®Google Scholar
• Dertzbaugh MT, West MW. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine 16, 1538–1544 (1996).
   Google Scholar
• Bittner MA, Das Gupta BR, Holz RW. Isolated light chains of botulinum neurotoxins inhibit exocytosis: studies in digitonin-permeabilized chromaffin cells. J. Biol. Chem. 264, 10354–10360 (1989).
   PubMed Web of Science ®Google Scholar
• Habermann E, Dreyer F. Clostridial neurotoxins: handling and action at the cellular and molecular level. Cun: Top. Microbial. Immunal 129, 93–179 (1986).
   Google Scholar
• Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. I Pharmacol Exp. Ther 212 (1), 16–21 (1980).
   Google Scholar
• Schiavo G, Benefenati F, Poulain B et al Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359, 832–835 (1992).
   PubMed Web of Science ®Google Scholar
• Ahnert-Hilger G, Bigalke H. Molecular aspects of tetanus and botulinum neurotoxin poisoning. Frog: Neumbial 46, 83–96 (1995).
   Google Scholar
• Barinaga M. Secrets of secretion revealed. Science 260, 487–489 (1993).
   PubMed Web of Science ®Google Scholar
• Callaway JE, Arezzo JC, Grethlein AJ. Botulinum toxin type B: an overview of its biochemistry and preclinical pharmacology. Sem. Cut. Med. Surg. 20(2), 127–136 (2001).
   Google Scholar
• ••This article provides a good review of the pharmacology and biochemistry of botulinum toxin type B.
   Google Scholar
• Moyer E, Setler PE. Botulinum toxin type B: experimental and clinical experience. In: TherapyffoTh botulinum toxin, neurological disease and therapy series, (Vol 25). Jankovic J, Hallet M, (Eds.), Marcel Dekkar, New York, USA 71–85 (1994).
   Google Scholar
• Botox® Product Monograph. Botox® Botulinum Toxin Type A Purified Neurotoxin Complex. Allergan, Inc, Irvine, California, USA 1998.
   Google Scholar
• Moyer ED, Stephens EA, Esch F, Litwak M, Arezzo J. Effects of im. injection of botulinum toxin type B in nonhuman primates. In: Botulinum and Tetanus Neurotoxins. DasGupta BR. Plenum Press, New York, USA (1993).
   Google Scholar
• Cherington M. Clinical spectrum of botulism. Muscle Nerve 21, 701–710 (1998).
   PubMed Web of Science ®Google Scholar
• Cichon JV, Jr., McCaffrey TV, Litchy WJ, Knops JL. The effects of botulinum toxin type A injection on compound muscle action potential in an in vivo rat model. Laryngoscope 2, 144–148 (1995).
   Google Scholar
• Meyer KE. A comparative systemic toxicity study of NeuroblocTm in adult and juvenile cynomolgus monkeys. Presented at the International Conference 1999: basic and therapeutic aspects of botulinum and tetanus toxin (poster). Orlando, FL. November 16–18 (1999).
   Google Scholar
• Brashear A, Lew ME, Dykstra DD et al Safety and efficacy of NeuroblocTm (botulinum toxin type B) in type A-responsive cervical dystonia. Neumlogy53, 1439–1446 (1999).
   PubMed Web of Science ®Google Scholar
• ••This pivotal study evaluates botulinum toxin type B in cervical dystonia patients who are responsive to type A toxin.
   Google Scholar
• Brin M, Lew MF, Adler CH et al Safety and efficacy of NeuroblocTm (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53, 1431–1438 (1999).
   PubMed Web of Science ®Google Scholar
• ••This pivotal study evaluates botulinum toxin type B in cervical dystonia patients who are resistant to type A toxin.
   Google Scholar
• Myobloc Package Insert, Elan Pharmaceuticals, South San Francisco, California, 2001.
   Google Scholar
• Cullis PA, O'Brien CF, Truong DD, Koller M, Villegas TP, Wallace JD. Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients. In: Dystonia 3 - advances in neurology Fahn S, Marsden CD, DeLong M, (Eds.), Lippincott-Raven, Philadelphia, USA 78, 227–230 (1998).
   Google Scholar
• Truong DD, Cullis PA, O'Brien CF et al Bot B (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study). May Disord 12, 772–775 (1997).
   PubMed Web of Science ®Google Scholar
• Tsui JKC, Hayward M, Mak EKM, Schulzer M. Botulinum toxin type B in the treatment of cervical dystonia: a pilot study. Neurology 45, 2109–2110 (1995).
   PubMed Web of Science ®Google Scholar
• American BotBTm Cervical Dystonia Study Group. BotB (botulinum toxin type B) in the treatment of cervical dystonia (CD) - protocol AN072-008: an interim analysis (abstract). May. Disord 10, 2874 (1995).
   Google Scholar
• Lew ME, Adornato BT, Duane DD et al Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 49, 701–707 (1997).
   PubMed Web of Science ®Google Scholar
• Cullis PA. Safety and effectiveness of Neurobloc (botulinum toxin type B solution): an open-label, dose-escalation study. Abstract book of the XVII World Congress of Neurology, London, UK, June 17–22, 2001. jPkumL&L 187\(Suppl. 1), S423 (2001).
   Google Scholar
• Data on file. Elan Pharmaceuticals, South San Francisco, California.
   Google Scholar
• Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology42, 878–882 (1992).
   PubMed Web of Science ®Google Scholar
• Riski JE, Homer J, Nashold BS, Jr. Swallowing function in patients with torticollis. Neurology 40, 1443–1445 (1990).
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Development Conference Statement, November 12–14, 1990. Clinical use of botulinum toxin. Arch. Neural. 48, 1294–1298 (1991).
   Google Scholar